Physician profile
Prabhat K Varma
NPI 1154329530
$4,404.34
in general payments reported to CMS, 2019-2025
26 companies · $20.93 in 2025
The $20.93 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,282 · 2020: $416 · 2021: $820 · 2022: $776 · 2023: $505 · 2024: $585 · 2025: $20.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,110.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $515.75 | 2020-2024 | Impella |
| Novartis Pharmaceuticals Corporation | $487.42 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.38 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $424.16 | 2019-2022 | |
| Amgen INC. | $380.46 | 2019-2023 | Repatha |
| Merck Sharp & Dohme LLC | $342.25 | 2021-2024 | Verquvo |
| Boston Scientific Corporation | $334.93 | 2019-2024 | Watchman Access System |
| Pfizer INC. | $316.12 | 2019-2023 | |
| Astellas Pharma US INC | $167.08 | 2019-2021 | |
| Edwards Lifesciences Corporation | $147.69 | 2019 | |
| Sanofi-Aventis U.S. LLC | $132.89 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $101.93 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $94.54 | 2021-2024 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $82.11 | 2019-2023 | Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $66.40 | 2021-2023 | Lifevest |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $51.65 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $50.09 | 2023 | Arcalyst |
| Bardy Diagnostics, INC. | $48.46 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $45.99 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $37.83 | 2023-2024 | |
| Vifor Pharma, INC. | $35.46 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $33.14 | 2021 | |
| Kestra Medical Technology Services, INC. | $20.93 | 2025 | Assure Wcd |
| Atricure, INC. | $17.91 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $17.25 | 2023 | Inpefa |
| Alnylam Pharmaceuticals INC. | $13.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prabhat Varma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.